Vergoeding 2017-2021 voor ATC-subgroep N03AX : Overige anti-epileptica
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| N03AX09 Lamotrigine (Lamictal ®) | 2.435.300 | 2.692.800 | 2.755.100 | 3.045.300 | 3.414.900 |
| N03AX10 Felbamaat (Taloxa ®) | 132.320 | 118.920 | 118.360 | 122.180 | 104.930 |
| N03AX11 Topiramaat (Topamax ®) | 905.010 | 1.107.300 | 1.297.500 | 1.433.700 | 1.444.200 |
| N03AX12 Gabapentine (Neurontin ®) | 1.388.300 | 1.584.900 | 1.875.600 | 1.948.400 | 2.133.100 |
| N03AX14 Levetiracetam (Keppra ®) | 4.735.900 | 5.208.800 | 5.187.500 | 6.781.300 | 7.088.700 |
| N03AX15 Zonisamide (Zonegran ®) | 438.840 | 383.930 | 367.090 | 371.670 | 365.730 |
| N03AX16 Pregabaline (Lyrica ®) | 23.870.500 | 9.328.700 | 8.463.000 | 9.089.800 | 7.480.400 |
| N03AX17 Stiripentol (Diacomit ®) | 450.470 | 451.630 | 423.970 | 410.690 | 419.460 |
| N03AX18 Lacosamide (Vimpat ®) | 3.569.500 | 4.198.300 | 4.920.600 | 5.480.400 | 5.513.700 |
| N03AX21 Retigabine | 1.488 | . | . | . | . |
| N03AX22 Perampanel (Fycompa ®) | 547.980 | 593.370 | 676.250 | 754.020 | 817.630 |
| N03AX23 Brivaracetam (Briviact ®) | 436.800 | 950.000 | 1.657.400 | 2.217.300 | 2.882.700 |
| Totaal | 38.912.408 | 26.618.650 | 27.742.370 | 31.654.760 | 31.665.450 |